98,665 results on '"costs and cost analysis"'
Search Results
2. Quality-Adjusted Life Year Proxies for Caries in Primary Dentition: A Discrete Choice Experiment
- Author
-
Lin, TK, Zarate, DE Arriola, Iribarren, N, Lindau, H, Ramos-Gomez, F, and Gansky, SA
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Infectious Diseases ,Cost Effectiveness Research ,Pain Research ,Good Health and Well Being ,experimental psychology ,consumer preferences ,behavioral economics ,value-based purchasing ,dental survey ,costs and cost analysis ,Tooth ,Deciduous ,Humans ,Herpes Labialis ,Gastritis ,Dental Caries ,Pain ,Cross-Sectional Studies ,Dental Caries Susceptibility ,Quality-Adjusted Life Years ,Quality of Life ,Child ,Dentistry - Abstract
IntroductionCost-utility analysis (CUA)-a method to evaluate intervention cost-effectiveness-transforms benefits of alternatives into a measure of quantity and quality of life, such as quality-adjusted life year (QALY), to enable comparison across heterogeneous programs. Measurement challenges prevent directly estimating utilities and calculating QALYs for caries in primary dentition. Proxy disease QALYs are often used as a substitute; however, there lacks quantitative evidence that these proxy diseases are comparable to caries.ObjectiveTo employ a discrete choice experiment (DCE) to quantitatively determine the most comparable proxy disease for different levels of caries in primary dentition.MethodsA cross-sectional DCE survey was administered to respondents (N = 461) who resided in California, were aged ≥18 y, and were primary caretakers for ≥1 child aged 3 to 12 y. Four attributes were included: pain level, disease duration, treatment cost, and family life impacts. Mixed effects logistic regression and conditional logistic regression were used to analyze the survey data.ResultsRespondents from the overall sample preferred no pain over mild (odds ratio [OR] = 0.50, P < 0.05), moderate (OR = 0.57, P < 0.05), and severe pain (OR = 0.48, P < 0.05). Acute gastritis (OR = 0.44, P < 0.05), chronic gastritis (OR = 0.31, P < 0.01), and cold sore (OR = 0.38, P < 0.05) were less preferred than stage 1 caries. Acute tonsilitis (OR = 0.43, P < 0.05), acute gastritis (OR = 0.38, P < 0.05), chronic gastritis (OR = 0.26, P < 0.01), and cold sore (OR = 0.33, P < 0.01) were less preferred than stage 2 caries. Chronic gastritis (OR = 0.42,P < 0.05) was less preferred than stage 4 caries.ConclusionsParents viewed the characteristics of many diseases with similar QALYs differently. Findings suggest that otitis media and its QALY-as commonly used in CUAs-may be a suitable proxy disease and substitute. However, other disease states with slightly different QALYs may be suitable. As such, the recommendation is to consider a range of proxy diseases and their QALYs when conducting a CUA for child caries interventions.Knowledge transfer statementThis study reviews and systematically compares pediatric diseases that are comparable to caries in primary dentition. The findings may inform future research using cost-utility analysis to examine the incremental cost-effectiveness ratio of interventions to prevent and treat caries as compared with an alternative.
- Published
- 2024
3. Provider costs of treating opioid dependence with extended‐release buprenorphine in Australia.
- Author
-
Settumba, Stella, Shahbazi, Jeyran, Byrne, Marianne, Degenhardt, Louisa, Grebely, Jason, Larance, Briony, Nielsen, Suzanne, Lintzeris, Nicholas, Ali, Robert, Rodgers, Craig, Blazey, Alison, Weiss, Robert, Dunlop, Adrian, McDonough, Michael, Cook, Jon, and Farrell, Michael
- Subjects
- *
SUBCUTANEOUS injections , *COST analysis , *HEALTH facilities , *MEDICAL care costs , *COST estimates - Abstract
Introduction Methods Results Discussion and Conclusion The costs of providing medication‐assisted treatment for opioid dependence can determine its scale of provision. To provide estimates of the costs of extended‐release buprenorphine (BUP‐XR), we performed a bottom‐up costing analysis of provider operational treatment costs.Data were collected in a single‐arm open label trial of BUP‐XR injections conducted in specialist public drug treatment services and primary care private practices in three Australian states (the CoLAB study). The unit costs of resources used for each activity were combined with quantities used at each participating facility to arrive at the average annual cost per client.One hundred participants across the six health facility sites received monthly subcutaneous BUP‐XR injections administered by a health‐care practitioner. The average cost of providing 1 year of treatment per participant was $6656 ($6026–$8326). Screening cost (initial assessment and medical history) was $282 while monthly follow‐up appointments cost $531 per client. The main cost driver was the monthly treatment costs accounting for 79% of the average annual client cost, with medication costs comprising 95% of this cost.With medication costs making up the largest proportion of treatment costs, treatment using BUP‐XR has the potential to free up other health system resources, for example, staff time. The costs reported in this study can be used in an economic evaluation to estimate the net benefit or cost‐effectiveness of BUP‐XR especially when compared to other opioid agonist treatments. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. The path to sustainable cardiac surgery in Rwanda: analysis of costs for consumables used during cardiac surgery for a non-governmental organization.
- Author
-
Rando, Hannah, Musoni, Maurice, Greenwood, Bonnie C., Ingabire, Lambert, Van Hook, Sam, Bolman, Ceeya Patton, Bolman III, R. Morton, and Lin, Yihan
- Subjects
- *
HIGH-income countries , *SURGICAL equipment , *PUBLIC health infrastructure , *NONGOVERNMENTAL organizations , *HEART valves - Abstract
Background: Until local healthcare infrastructure is strengthened, cardiac surgical care in low- and middle-income countries is often provided by non-governmental organizations by way of visiting healthcare teams. This is generally considered to be a cost-effective alternative to transporting patients to high income countries for surgical care, but the costs of cardiac surgery consumables under this model are poorly understood. Our objective was to identify the per-patient cost of cardiac surgery consumables used in single and double valve replacements performed by a non-governmental organization in Rwanda. Methods: Financial data from 2020 were collected from Team Heart, a non-governmental organization that supports cardiac surgical care in Rwanda. A comprehensive list of consumables was generated, including surgical, perfusion, anesthesia, and inpatient supplies and medications. Acknowledging the variability in perioperative needs, the quantities of consumables were calculated from an average of six patients who underwent single or double-valve replacement in 2020. Total costs were calculated by multiplying purchasing price by average quantity per patient. Costs absorbed by the local hospital were excluded from the calculations. Results: The total cost per patient was estimated at $9,450. Surgical supplies comprised the majority of costs ($6,140 per patient), with the most substantial cost being that of replacement valves ($3,500 per valve), followed by surgical supplies ($1,590 per patient). Conclusions: This preliminary analysis identifies a cost of just over $9,000 per patient for consumables used in cardiac valve surgery in Rwanda, which is lower than the estimated costs of transporting patients to centers in high income countries. This work highlights the relative cost effectiveness of cardiac surgical care in low- and middle- income countries under this model and will be instrumental in guiding the allocation of local and international resources in the future. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Cost-effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration and its Subtypes from the Societal and Patient Perspectives in Japan.
- Author
-
Yanagi, Yasuo, Takahashi, Kanji, Iida, Tomohiro, Gomi, Fumi, Onishi, Hiroshi, Morii, Junko, and Sakamoto, Taiji
- Subjects
- *
MACULAR degeneration , *ENDOTHELIAL growth factors , *POLYPOIDAL choroidal vasculopathy , *PATIENTS' attitudes , *QUALITY-adjusted life years - Abstract
Introduction: This study evaluated the cost-effectiveness of anti-vascular endothelial growth factor (VEGF) therapies for subtypes of neovascular age-related macular degeneration (nAMD) from the societal perspective, and for any nAMD from the patient perspective in Japan. Methods: A Markov model was developed to simulate the lifetime transitions of a cohort of patients with nAMD through various health states based on the involvement of nAMD, the treatment status, and decimal best-corrected visual acuity. Ranibizumab biosimilar was compared with aflibercept from the societal perspective regardless of treatment regimen for the analysis of three subtypes (typical nAMD, polypoidal choroidal vasculopathy (PCV), and retinal angiomatous proliferation (RAP)). Two analyses from the patient perspective focusing on the treat-and-extend regimens were performed, one with a cap on patients' copayments and one without. Ranibizumab biosimilar was compared with branded ranibizumab, aflibercept, aflibercept as the loading dose switching to ranibizumab biosimilar during maintenance (aflibercept switching to ranibizumab biosimilar), and best supportive care (BSC), for patients with any nAMD. Results: In the subtype analyses, ranibizumab biosimilar when compared with aflibercept resulted in incremental quality-adjusted life years (QALYs) of − 0.015, 0.026, and 0.009, and the incremental costs of Japanese yen (JPY) − 50,447, JPY − 997,243, and JPY − 1,286,570 for typical nAMD, PCV, and RAP, respectively. From the patient perspective, ranibizumab biosimilar had incremental QALYs of 0.015, 0.009, and 0.307, compared with aflibercept, aflibercept switching to ranibizumab biosimilar, and BSC, respectively. The incremental costs for ranibizumab biosimilar over a patient lifetime excluding the cap on copayment were estimated to be JPY − 138,948, JPY − 391,935, JPY − 209,099, and JPY − 6,377,345, compared with branded ranibizumab, aflibercept, aflibercept switching to ranibizumab biosimilar, and BSC, respectively. Conclusions: Ranibizumab biosimilar was demonstrated as a cost-saving option compared to aflibercept across all subtypes of nAMD, irrespective of the perspectives considered. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
6. Glycemic Outcomes and Nurse Perceptions of Continuous Glucose Monitoring for Hospitalized Patients.
- Author
-
Thullen, Alexandra, Gerber, Rebecca, and Keen, Alyson
- Subjects
BLOOD sugar analysis ,HEALTH services accessibility ,CONTINUING education units ,HEALTH attitudes ,ACADEMIC medical centers ,PATIENT safety ,HOSPITAL care ,HOSPITAL nursing staff ,INTERVIEWING ,STATISTICAL sampling ,CONTENT analysis ,NURSING ,PRE-tests & post-tests ,CONTINUOUS glucose monitoring ,NURSES' attitudes ,RESEARCH methodology ,LENGTH of stay in hospitals ,PATIENT monitoring ,POINT-of-care testing ,HYPOGLYCEMIA ,MEDICAL care costs - Abstract
Background: Continuous glucose monitoring (CGM) can decrease hypoglycemic events and health care costs; however, barriers and facilitators that influence CGM use are unknown. Purpose: The purpose of this study was to evaluate hypoglycemic events and cost outcomes after CGM implementation and describe associated barriers and facilitators. Methods: A mixed-methods study design was used to evaluate CGM implementation on 2 pulmonary units within an academic health center. Hypoglycemic events were evaluated before and after CGM implementation, and nurses were interviewed about facilitators and barriers that influence CGM use. Results: Hypoglycemic events decreased from a rate of 0.0906 per 1000 patient days to 0.0503 postimplementation, P < .0001. A $105 766 cost avoidance was recognized. Barriers and facilitators to CGM use are described. Conclusions: Findings support CGM implementation, while uniquely contributing financial impact and device use barriers and facilitators. Hospitals may consider CGM use to improve timely identification and treatment of hypoglycemia. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Cost analysis of orthognathic surgery: outpatient care versus inpatient care.
- Author
-
Pekkari, C., Lund, B., Davidson, T., Naimi-Akbar, A., Marcusson, A., and Weiner, C.K.
- Subjects
COST analysis ,INPATIENT care ,MAXILLARY expansion ,OUTPATIENT medical care ,MEDICAL care costs ,ORTHOGNATHIC surgery - Abstract
With limited healthcare resources, it is important to provide the right level and form of care. The aim of this study was to determine whether selected single-jaw orthognathic surgery in outpatient care (OPC) generates lower healthcare costs than in inpatient care (IPC). The costs of surgically assisted rapid maxillary expansion (SARME), Le Fort I osteotomy (LFI), and bilateral sagittal split osteotomy (BSSO) were calculated for 165 patients, 107 treated in OPC and 58 in IPC. Additionally, costs for revisits, emergency visits, emergency phone calls, re-operations, and plate removal during the first 12 months postoperatively were recorded. The total mean costs of the different operations including revisits, emergency visits, and phone calls were 34.2–48.8% lower in OPC than in IPC at 12 months postoperatively. Operation costs were lower for LFI in OPC (P = 0.009) and for SARME in IPC (P = 0.007). Anaesthesia costs were lower for LFI (P < 0.001) and BSSO (P < 0.001) in OPC, and there were fewer revisits (P = 0.001) and lower costs (P = 0.002) after LFI in OPC compared to IPC. This study showed that selected single-jaw orthognathic surgeries in outpatient care are associated with lower healthcare costs compared to inpatient care. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Global structures, practices, and tools for provision of hemodialysis.
- Author
-
Htay, Htay, Cho, Yeoungjee, Jha, Vivekanand, See, Emily, Arruebo, Silvia, Caskey, Fergus J, Damster, Sandrine, Donner, Jo-Ann, Levin, Adeera, Nangaku, Masaomi, Saad, Syed, Tonelli, Marcello, Ye, Feng, Okpechi, Ikechi G, Bello, Aminu K, and Johnson, David W
- Subjects
- *
RENAL replacement therapy , *LOW-income countries , *HIGH-income countries , *KIDNEY failure ,WESTERN countries - Abstract
Background Hemodialysis (HD) is the most commonly utilized modality for kidney replacement therapy worldwide. This study assesses the organizational structures, availability, accessibility, affordability and quality of HD care worldwide. Methods This cross-sectional study relied on desk research data as well as survey data from stakeholders (clinicians, policymakers and patient advocates) from countries affiliated with the International Society of Nephrology from July to September 2022. Results Overall, 167 countries or jurisdictions participated in the survey. In-center HD was available in 98% of countries with a median global prevalence of 322.7 [interquartile range (IQR) 76.3–648.8] per million population (pmp), ranging from 12.2 (IQR 3.9–103.0) pmp in Africa to 1575 (IQR 282.2–2106.8) pmp in North and East Asia. Overall, home HD was available in 30% of countries, mostly in countries of Western Europe (82%). In 74% of countries, more than half of people with kidney failure were able to access HD. HD centers increased with increasing country income levels from 0.31 pmp in low-income countries to 9.31 pmp in high-income countries. Overall, the annual cost of in-center HD was US$19 380.3 (IQR 11 817.6–38 005.4), and was highest in North America and the Caribbean (US$39 825.9) and lowest in South Asia (US$4310.2). In 19% of countries, HD services could not be accessed by children. Conclusions This study shows significant variations that have remained consistent over the years in availability, access and affordability of HD across countries with severe limitations in lower-resourced countries. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
9. Comparative analysis of inpatient costs for the surgical treatment of distal radial fractures in children and adults: a retrospective cohort study from a single surgeon's experience.
- Author
-
Kim, Yun Ki, Lee, Seung-Ho, and Lee, Seung Hoo
- Subjects
- *
DISTAL radius fractures , *WRIST fractures , *RADIUS fractures , *BONE plates (Orthopedics) , *CHILD patients , *FLUOROSCOPY - Abstract
Purpose: Distal radial fractures are common in children and older adults, and numerous studies have analyzed their medical costs. However, no study has attempted to compare the medical costs of distal radial fractures in children and adults requiring surgical treatment in Korea. We therefore investigated this issue for the first time. Methods: The study retrospectively analyzed 96 pediatric and adult patients who underwent surgery for distal radial fractures performed by a single surgeon between January 2021 and January 2023. Patients were divided into adult (>16 years) and pediatric (≤16 years) groups. We examined patients' demographic factors, surgical details, and inpatient costs. Results: The average total inpatient cost in the pediatric group was 1,640,000 Korean won (KRW), compared to 2,940,000 KRW in the adult group. The largest difference was in surgical material costs, which were approximately 700,000 KRW more expensive in adults. Kirschner wires were mainly used during surgery for pediatric patients, whereas volar locking plates were mainly used for adults. The number of C-arm fluoroscopy images obtained during surgery was higher in pediatric patients than in adults. The reoperation rate was higher in pediatric patients. Conclusion: The inpatient costs of surgical treatment for pediatric patients with distal radius fractures were lower than for adults, primarily due to differences in the costs of surgical materials. However, the reoperation rate was higher in the pediatric group, and radiation exposure was also greater. Policy adjustments may be necessary to address these unique challenges in the treatment of pediatric wrist fractures. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Development and implementation of ambulatory care pharmacy services at an internal medicine clinic.
- Author
-
Wells, Casey, Warren, Anne Carrington, and Scott, Mollie Ashe
- Subjects
- *
PATIENT compliance , *HYPERCHOLESTEREMIA , *PHARMACY education , *OUTPATIENT medical care , *HEALTH insurance , *DIABETIC nephropathies , *GLYCEMIC control , *HYPERTENSION , *COST analysis , *INTERNSHIP programs , *MEDICATION reconciliation , *PATIENT-centered care , *BLOOD sugar , *PHARMACY information services , *INTERNAL medicine , *EYE examination , *MEDICATION therapy management , *DRUGSTORES , *NEEDS assessment , *DRUGS , *DEMOGRAPHY , *DIABETES - Abstract
Purpose This report describes the step-by-step process that led to expansion of ambulatory care pharmacy services at a newly established internal medicine clinic within a patient-centered medical home in North Carolina. Summary Implementation of clinical pharmacist services at the clinic was led by a postgraduate year 2 (PGY2) pharmacy resident and guided by the 9 steps described in the book Building a Successful Ambulatory Care Practice: A Complete Guide for Pharmacists. After a needs assessment and review of the demographics and insurance status of the clinic's target population, it was determined that pharmacist services would focus on quality measures including diabetes nephropathy screening, diabetes eye examination, blood glucose control in diabetes, discharge medication reconciliation, annual wellness visits, and medication adherence in diabetes, hypercholesterolemia, and hypertension. Clinic appointments were conducted under 3 models: a pharmacist-physician covisit model, a "floor model" of pharmacist consultation on drug information or medication management issues during medical resident sign-out sessions with supervising physicians (medical residents could also see patients along with the pharmacist at a covisit appointment), and a covisit model of stacked physician and pharmacist appointments. The pharmacist's services were expanded from 2 half-day clinic sessions per week initially to 5 or 6 half-day clinic sessions by the end of the residency year. Conclusion By the fourth quarter of the first PGY2 residency year in which ambulatory care pharmacy services were provided in the clinic, the clinical and financial impact of those services justified the addition of a second full-time pharmacist to the clinic team. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Estimation of the direct health and indirect societal costs of diabetes in the UK using a cost of illness model.
- Author
-
Hex, Nick, MacDonald, Rachael, Pocock, Jessica, Uzdzinska, Barbara, Taylor, Matthew, Atkin, Marc, Wild, Sarah H., Beba, Hannah, and Jones, Ross
- Subjects
- *
DIAGNOSIS of diabetes , *TREATMENT of diabetes , *DIABETES complications , *TYPE 1 diabetes , *STATISTICAL models , *MORTALITY , *INTERPROFESSIONAL relations , *JOB absenteeism , *GESTATIONAL diabetes , *DISEASE prevalence , *TYPE 2 diabetes , *CONCEPTUAL structures , *ECONOMIC aspects of diseases , *MEDICAL care costs , *DIABETES - Abstract
Aims: The direct cost of diabetes to the UK health system was estimated at around £10 billion in 2012. This analysis updates that estimate using more recent and accurate data sources. Methods: A pragmatic review of relevant data sources for UK nations was conducted, including population‐level data sets and published literature, to generate estimates of costs separately for Type 1, Type 2 and gestational diabetes. A comprehensive cost framework, developed in collaboration with experts, was used to create a population‐based cost of illness model. The key driver of the analysis was prevalence of diabetes and its complications. Estimates were made of the excess costs of diagnosis, treatment and diabetes‐related complications compared with the general UK population. Estimates of the indirect costs of diabetes focused on productivity losses due to absenteeism and premature mortality. Results: The direct costs of diabetes in 2021/22 for the UK were estimated at £10.7 billion, of which just over 40% related to diagnosis and treatment, with the rest relating to the excess costs of complications. Indirect costs were estimated at £3.3 billion. Conclusions: Diabetes remains a considerable cost burden in the UK, and the majority of those costs are still spent on potentially preventable complications. Although rates of some complications are reducing, prevalence continues to increase and effective approaches to primary and secondary prevention continue to be needed. Improvements in data capture, data quality and reporting, and further research on the human and financial implications of increasing incidence of Type 2 diabetes in younger people are recommended. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. A scoping review of costing methodologies used to assess interventions for underserved pregnant people and new parents.
- Author
-
Darling, Elizabeth K., Jansen, Aisha, Jameel, Bismah, and Tarride, Jean-Éric
- Subjects
- *
HEALTH services accessibility , *MEDICAL information storage & retrieval systems , *HOME care services , *SMOKING cessation , *MEDICALLY underserved areas , *MENTAL health services , *RESEARCH funding , *CINAHL database , *COST analysis , *PREGNANT women , *DESCRIPTIVE statistics , *PRENATAL care , *SYSTEMATIC reviews , *MEDLINE , *LITERATURE reviews , *MEDICAL databases , *COMPARATIVE studies , *HEALTH equity , *MEDICALLY underserved persons , *PSYCHOSOCIAL factors , *MEDICAL care costs - Abstract
Background: Lack of evidence about the long-term economic benefits of interventions targeting underserved perinatal populations can hamper decision making regarding funding. To optimize the quality of future research, we examined what methods and costs have been used to assess the value of interventions targeting pregnant people and/or new parents who have poor access to healthcare. Methods: We conducted a scoping review using methods described by Arksey and O'Malley. We conducted systematic searches in eight databases and web-searches for grey literature. Two researchers independently screened results to determine eligibility for inclusion. We included economic evaluations and cost analyses of interventions targeting pregnant people and/or new parents from underserved populations in twenty high income countries. We extracted and tabulated data from included publications regarding the study setting, population, intervention, study methods, types of costs included, and data sources for costs. Results: Final searches were completed in May 2024. We identified 103 eligible publications describing a range of interventions, most commonly home visiting programs (n = 19), smoking cessation interventions (n = 19), prenatal care (n = 11), perinatal mental health interventions (n = 11), and substance use treatment (n = 10), serving 36 distinct underserved populations. A quarter of the publications (n = 25) reported cost analyses only, while 77 were economic evaluations. Most publications (n = 82) considered health care costs, 45 considered other societal costs, and 14 considered only program costs. Only a third (n = 36) of the 103 included studies considered long-term costs that occurred more than one year after the birth (for interventions occurring only in pregnancy) or after the end of the intervention. Conclusions: A broad range of interventions targeting pregnant people and/or new parents from underserved populations have the potential to reduce health inequities in their offspring. Economic evaluations of such interventions are often at risk of underestimating the long-term benefits of these interventions because they do not consider downstream societal costs. Our consolidated list of downstream and long-term costs from existing research can inform future economic analyses of interventions targeting poorly served pregnant people and new parents. Comprehensively quantifying the downstream and long-term benefits of such interventions is needed to inform decision making that will improve health equity. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Medication reviews by emergency department pharmacists in patients hospitalised for an adverse drug event: a cost study.
- Author
-
Rahman, Rehana N., Polinder, Suzanne, Nikolik, Bojan, Hoek, Amber E., Janssen, Marjo J. A., Schuit, Stephanie C. E., van den Bemt, Patricia M.L.A., and Karapinar-Çarkit, Fatma
- Subjects
- *
EMERGENCY room visits , *DRUG side effects , *HOSPITAL costs , *HOSPITAL emergency services , *HOSPITAL charges - Abstract
Objective: To perform a cost study of pharmacist-led medication reviews in patients with an acute hospitalization for adverse drug events. Method: Emergency department pharmacists performed medication reviews in patients hospitalized after visiting the emergency department for an adverse drug event (ADE). Control patients were hospitalized after an emergency department visit not related to an ADE and received usual care. The costs of the intervention were labour costs of the junior emergency department pharmacist and the cost savings consisted of costs of medication that was stopped or reduced during six months after the intervention. Sensitivity analyses were performed to evaluate different scenarios. Results: In the intervention group (n = 104) 113 medication changes led to stopping or reducing medication, accounting for averted costs of €22,850. In the control group (n = 112) 39 medication changes led to stopping or reducing medication, accounting for averted costs of €299. The mean labour costs of the intervention were €138 per patient, resulting in saved costs of €61 per patient per six months. Sensitivity analyses showed that if the intervention would be performed by a senior clinical pharmacist, there are no cost savings (€-21), if parts of the intervention would be executed by pharmacy technicians (e.g. administrative tasks), cost savings would be augmented to €87, if outliers in costs associated with medication reduction would be excluded, there are no cost savings (€-35) and if the costs of reduced medication were extrapolated to one year, cost savings would be €260. Conclusion: In this study, medication reviews by junior emergency department pharmacists in patients hospitalized after an emergency department visit for an ADE lead to a cost reduction over a six month period. Trial registration: The main study is registered on the ISRCTN registry with trial ID ISRCTN12506329 on 06-03-2022. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Episodic Cost of Lower Respiratory Tract Illness due to Respiratory Syncytial Virus Among US Infants During the First Year of Life.
- Author
-
Averin, Ahuva, Law, Amy, Shea, Kimberly, Atwood, Mark, Munjal, Iona, and Weycker, Derek
- Subjects
- *
RESPIRATORY syncytial virus infections , *RESPIRATORY syncytial virus , *GESTATIONAL age , *COST analysis , *ACUTE diseases - Abstract
A study of 2 health care claims databases (commercial, Medicaid) was undertaken to estimate the episodic cost of lower respiratory tract illness due to respiratory syncytial virus among infants aged <12 months overall, by age, and by birth gestational age. Among commercial-insured infants, mean costs were $28 812 for hospitalized episodes, $2575 for emergency department episodes, and $336 for outpatient clinic episodes. Costs were highest among infants aged <1 month and infants with a gestational age ≤32 weeks and were comparable among Medicaid-insured infants, albeit somewhat lower. The cost of lower respiratory tract illness due to respiratory syncytial virus during the acute phase of illness is high, especially among the youngest infants and those born premature. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Burden of disease and direct costs to the health system attributable to high body mass index in Brazil.
- Author
-
Rocha, L.P., Machado, Í.E., Fogal, A.S., Malta, D.C., Velasquez-Melendez, G., and Felisbino-Mendes, M.S.
- Subjects
- *
CROSS-sectional method , *BODY mass index , *GOVERNMENT policy , *COST effectiveness , *HOSPITAL care , *GLOBAL burden of disease , *DESCRIPTIVE statistics , *DATA analysis software , *MEDICAL care costs , *ECOLOGICAL research , *ECONOMIC aspects of diseases , *SOCIAL classes - Abstract
Excess weight, measured by a high body mass index (BMI), is associated with the onset of many diseases, which can, in turn, lead to disability and premature death, subsequently placing a significant burden on healthcare services. This study analysed the burden of disease and the direct costs to the Brazilian Unified Health System (Sistema Único de Saúde [SUS]) attributable to high BMI in the Brazilian population. Ecological study. This ecological study had two components: (1) a time-series assessment to analyse the burden of diseases attributable to high BMI from 1990 to 2019 in Brazil; and (2) a cross-sectional design to estimate the direct costs of SUS hospitalisations and outpatient procedures attributable to high BMI in 2019. Estimates from the Global Burden of Disease study and the costs of hospital admissions and outpatient procedures from the Department of Informatics of the Brazilian Unified Health System were used. Deaths, years of life lost to premature death (YLLs), years lived with disability (YLDs), and years of life lost adjusted for disability (DALYs) were analysed. The direct health cost was obtained in Brazilian Real (R$) and converted in international Dollars (INT$). The current study found a reduction in the number of DALYs, YLLs, and deaths per 100,000 population of cardiovascular disease (CVD) attributable to high BMI and an increase in YLD due to diabetes and cardiovascular disease attributable to high BMI from 1990 to 2019. In 2019, high BMI resulted in 2404 DALYs, 658 YLDs, 1746 YLLs, and 76 deaths per 100,000 inhabitants. In the same year, INT$377.30 million was spent on hospitalisations and high- and medium-complexity procedures to control non-communicable diseases attributable to high BMI. The states in the South and Southeast regions of Brazil presented the highest total cost per 10,000 inhabitants. CVDs and chronic kidney disease showed the highest costs per hospital admission, whereas neoplasms and CVDs presented the highest costs for outpatient procedures. High BMI causes significant disease burden and financial costs. The highest expenses observed were not in locations with the highest burden of disease attributable to high BMI. These findings highlight the need to improve current public policies and apply cost-effective intervention packages, focussing on equity and the promotion of healthier lifestyles to reduce overweight/obesity, especially in localities with low socioeconomic status. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Potential healthcare resource use and associated costs of every 2 month injectable cabotegravir plus rilpivirine long-acting regimen implementation in the Spanish National Healthcare System compared to daily oral HIV treatments.
- Author
-
Aparicio, Laura-Amanda Vallejo, García, Victoria Neches, Hernández-Novoa, Beatriz, Casado, Gregorio, Jodar, Ferrán, Pinel, Marco, and Velasco, Daniel Callejo
- Abstract
Introduction: HIV treatment currently consists of daily oral antiretroviral therapy (ART). Cabotegravir + rilpivirine long-acting (CAB + RPV LA) is the first ART available in Spain administered every 2 months through intramuscular injection by a healthcare professional (HCP). The objective of this analysis was to assess potential healthcare resource use (HRU) and cost impact of implementing CAB + RPV LA vs. daily oral ART at National Health System (NHS) hospitals. Methods: Online quantitative interviews and cost analysis were performed. Infectious disease specialists (IDS), hospital pharmacists (HP) and nurses were asked about their perception of potential differences in HRU between CAB + RPV LA vs. daily oral ART, among other concepts of interest. Spanish official tariffs were applied as unit costs to the HRU estimates (€2022). Results: 120 responders (n = 40 IDS, n = 40 HP, n = 40 nurses) estimated an average number of annual visits per patient by speciality (IDS, HP, and nurse, respectively) of 3.3 vs. 3.7; 4.4 vs. 6.2; 6.1 vs. 3.9, for CAB + RPV LA vs. daily oral ART, and 3.0 vs. 3.2; 4.8 vs. 5.8; 6.9 vs. 4.9, respectively when adjusting by corresponding specialist responses. Estimation by the total sample led to an annual total cost per patient of €2,076 vs. €2,473, being €2,032 vs. €2,237 after adjusting by corresponding HCP, for CAB + RPV LA vs. daily oral ART. Conclusions: These results suggest that the implementation of CAB + RPV LA in NHS hospitals would not incur in increased HRU-related costs compared to current daily oral ARTs, being potentially neutral or even cost-saving. Why carry out this study? • Main clinical guidelines in HIV recommend the use of daily oral antiretroviral combinations. Recently, a long-acting regimen consisting of cabotegravir plus rilpivirine (CAB + RPV LA) gluteal intramuscular injections has become available in Spain for maintaining HIV-1 suppression. • Given that the long-acting regimes are administered every 2 months, it is anticipated to have a different patient pathway within the hospital compared to daily oral ART, which may lead to changes in healthcare resources and associated costs needed for HIV treatment. What was learned from the study? • The total annual cost per patient ranged from €2,032 to €2,076 for CAB + RPV LA, and from €2,237 to €2,473 for daily oral ART. • These figures suggest that the implementation of CAB + RPV LA in Spanish NHS hospitals would not translate into increased healthcare resource utilization-related costs associated to a different patient pathway compared to current daily oral ART, being potentially cost-saving. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Prosocial motives underlie scientific censorship by scientists: A perspective and research agenda.
- Author
-
Clark, Cory, Jussim, Lee, Frey, Komi, Stevens, Sean, Al-Gharbi, Musa, Aquino, Karl, Bailey, J, Barbaro, Nicole, Baumeister, Roy, Bleske-Rechek, April, Buss, David, Ceci, Stephen, Del Giudice, Marco, Ditto, Peter, Forgas, Joseph, Geary, David, Geher, Glenn, Haider, Sarah, Honeycutt, Nathan, Joshi, Hrishikesh, Krylov, Anna, Loury, Glenn, Lu, Louise, Macy, Michael, Martin, Chris, McWhorter, John, Miller, Geoffrey, Paresky, Pamela, Pinker, Steven, Reilly, Wilfred, Salmon, Catherine, Stewart-Williams, Steve, Tetlock, Philip, Williams, Wendy, Wilson, Anne, Winegard, Bo, Yancey, George, von Hippel, William, and Loftus, Elizabeth
- Subjects
academic freedom ,censorship ,organizational behavior ,science reform ,transparency ,Costs and Cost Analysis ,Censorship ,Research ,Science ,Social Responsibility - Abstract
Science is among humanitys greatest achievements, yet scientific censorship is rarely studied empirically. We explore the social, psychological, and institutional causes and consequences of scientific censorship (defined as actions aimed at obstructing particular scientific ideas from reaching an audience for reasons other than low scientific quality). Popular narratives suggest that scientific censorship is driven by authoritarian officials with dark motives, such as dogmatism and intolerance. Our analysis suggests that scientific censorship is often driven by scientists, who are primarily motivated by self-protection, benevolence toward peer scholars, and prosocial concerns for the well-being of human social groups. This perspective helps explain both recent findings on scientific censorship and recent changes to scientific institutions, such as the use of harm-based criteria to evaluate research. We discuss unknowns surrounding the consequences of censorship and provide recommendations for improving transparency and accountability in scientific decision-making to enable the exploration of these unknowns. The benefits of censorship may sometimes outweigh costs. However, until costs and benefits are examined empirically, scholars on opposing sides of ongoing debates are left to quarrel based on competing values, assumptions, and intuitions.
- Published
- 2023
18. The path to sustainable cardiac surgery in Rwanda: analysis of costs for consumables used during cardiac surgery for a non-governmental organization
- Author
-
Hannah Rando, Maurice Musoni, Bonnie C. Greenwood, Lambert Ingabire, Sam Van Hook, Ceeya Patton Bolman, R. Morton Bolman, and Yihan Lin
- Subjects
Costs and cost analysis ,Cardiac surgical procedures ,Developing countries ,Global health ,Surgery ,RD1-811 ,Anesthesiology ,RD78.3-87.3 - Abstract
Abstract Background Until local healthcare infrastructure is strengthened, cardiac surgical care in low- and middle-income countries is often provided by non-governmental organizations by way of visiting healthcare teams. This is generally considered to be a cost-effective alternative to transporting patients to high income countries for surgical care, but the costs of cardiac surgery consumables under this model are poorly understood. Our objective was to identify the per-patient cost of cardiac surgery consumables used in single and double valve replacements performed by a non-governmental organization in Rwanda. Methods Financial data from 2020 were collected from Team Heart, a non-governmental organization that supports cardiac surgical care in Rwanda. A comprehensive list of consumables was generated, including surgical, perfusion, anesthesia, and inpatient supplies and medications. Acknowledging the variability in perioperative needs, the quantities of consumables were calculated from an average of six patients who underwent single or double-valve replacement in 2020. Total costs were calculated by multiplying purchasing price by average quantity per patient. Costs absorbed by the local hospital were excluded from the calculations. Results The total cost per patient was estimated at $9,450. Surgical supplies comprised the majority of costs ($6,140 per patient), with the most substantial cost being that of replacement valves ($3,500 per valve), followed by surgical supplies ($1,590 per patient). Conclusions This preliminary analysis identifies a cost of just over $9,000 per patient for consumables used in cardiac valve surgery in Rwanda, which is lower than the estimated costs of transporting patients to centers in high income countries. This work highlights the relative cost effectiveness of cardiac surgical care in low- and middle- income countries under this model and will be instrumental in guiding the allocation of local and international resources in the future.
- Published
- 2024
- Full Text
- View/download PDF
19. Cost-effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration and its Subtypes from the Societal and Patient Perspectives in Japan
- Author
-
Yasuo Yanagi, Kanji Takahashi, Tomohiro Iida, Fumi Gomi, Hiroshi Onishi, Junko Morii, and Taiji Sakamoto
- Subjects
Cost-effectiveness ,Costs and cost analysis ,Japan ,Neovascular age-related macular degeneration ,Patient perspective ,Polypoidal choroidal vasculopathy ,Ophthalmology ,RE1-994 - Abstract
Abstract Introduction This study evaluated the cost-effectiveness of anti-vascular endothelial growth factor (VEGF) therapies for subtypes of neovascular age-related macular degeneration (nAMD) from the societal perspective, and for any nAMD from the patient perspective in Japan. Methods A Markov model was developed to simulate the lifetime transitions of a cohort of patients with nAMD through various health states based on the involvement of nAMD, the treatment status, and decimal best-corrected visual acuity. Ranibizumab biosimilar was compared with aflibercept from the societal perspective regardless of treatment regimen for the analysis of three subtypes (typical nAMD, polypoidal choroidal vasculopathy (PCV), and retinal angiomatous proliferation (RAP)). Two analyses from the patient perspective focusing on the treat-and-extend regimens were performed, one with a cap on patients’ copayments and one without. Ranibizumab biosimilar was compared with branded ranibizumab, aflibercept, aflibercept as the loading dose switching to ranibizumab biosimilar during maintenance (aflibercept switching to ranibizumab biosimilar), and best supportive care (BSC), for patients with any nAMD. Results In the subtype analyses, ranibizumab biosimilar when compared with aflibercept resulted in incremental quality-adjusted life years (QALYs) of − 0.015, 0.026, and 0.009, and the incremental costs of Japanese yen (JPY) − 50,447, JPY − 997,243, and JPY − 1,286,570 for typical nAMD, PCV, and RAP, respectively. From the patient perspective, ranibizumab biosimilar had incremental QALYs of 0.015, 0.009, and 0.307, compared with aflibercept, aflibercept switching to ranibizumab biosimilar, and BSC, respectively. The incremental costs for ranibizumab biosimilar over a patient lifetime excluding the cap on copayment were estimated to be JPY − 138,948, JPY − 391,935, JPY − 209,099, and JPY − 6,377,345, compared with branded ranibizumab, aflibercept, aflibercept switching to ranibizumab biosimilar, and BSC, respectively. Conclusions Ranibizumab biosimilar was demonstrated as a cost-saving option compared to aflibercept across all subtypes of nAMD, irrespective of the perspectives considered.
- Published
- 2024
- Full Text
- View/download PDF
20. Different doses of vonoprazan as the first-line treatment of Helicobacter pylori infection: A prospective cohort study
- Author
-
SUN Ziming, WANG Shaojun, LIU Dongyue, XIU Hui, WANG Rongyu, LIU Xishuang
- Subjects
proton pump inhibitors ,omeprazole ,helicobacter pylori ,disease eradication ,costs and cost analysis ,Medicine - Abstract
Objective To investigate the efficacy, safety, compliance, and economic benefits of low-dose or standard-dose vonoprazan quadruple therapy for the eradication of Helicobacter pylori (Hp). Methods A total of 531 patients who were diagnosed with Hp infection in our hospital from March to August 2023 were enrolled and divided into esomeprazole (Ebid) group (oral administration of esomeprazole 20 mg twice a day), standard vonoprazan (Vbid) group (oral administration of vonoprazan 20 mg twice a day), and low-dose vonoprazan (Vqd) group (oral administration of vonoprazan 20 mg once a day), and the remaining three drugs of Hp quadruple therapy were the same for the three groups (oral administration of amoxicillin 1 000 mg, cla-rithromycin 500 mg, and bismuth potassium citrate 600 mg, twice a day), with a course of treatment of 14 days. All patients were examined for Hp eradication rate (based on the intention-to-treat [ITT] analysis and the per-protocol [PP] analysis), symptom improvement, adverse events, and patient compliance after 4 weeks of drug withdrawal, and a cost-effectiveness analysis was pe-rformed for the regimens in each group (including the ITT and PP analyses). Results There was a significant difference in Hp eradication rate between the three groups in the ITT and PP analyses (χ2ITT=6.351,PITT0.05). All three groups had mild adverse events, and the Vqd group had a significantly lower incidence rate of adverse events than the Ebid group (χ2=6.058,P0.05), with a compliance rate of >95% in all three groups. The Vqd group had a lower cost-effectiveness ratio than the Vbid and Ebid groups in both ITT and PP analyses. Conclusion The low-dose vonoprazan quadruple regimen has comparable efficacy to the standard-dose regimen, and both regimens have better efficacy than esomeprazole quadruple regimen. The low-dose vonoprazan quadruple regimen has better safety and cost-effectiveness and thus holds promise for clinical application in Hp eradication therapy.
- Published
- 2024
- Full Text
- View/download PDF
21. Medication reviews by emergency department pharmacists in patients hospitalised for an adverse drug event: a cost study
- Author
-
Rehana N. Rahman, Suzanne Polinder, Bojan Nikolik, Amber E. Hoek, Marjo J. A. Janssen, Stephanie C. E. Schuit, Patricia M.L.A. van den Bemt, and Fatma Karapinar-Çarkit
- Subjects
Drug-related side effects and adverse reactions ,Hospital emergency service ,Health care costs ,Medical overuse ,Costs and cost analysis ,Drug utilization review ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Objective To perform a cost study of pharmacist-led medication reviews in patients with an acute hospitalization for adverse drug events. Method Emergency department pharmacists performed medication reviews in patients hospitalized after visiting the emergency department for an adverse drug event (ADE). Control patients were hospitalized after an emergency department visit not related to an ADE and received usual care. The costs of the intervention were labour costs of the junior emergency department pharmacist and the cost savings consisted of costs of medication that was stopped or reduced during six months after the intervention. Sensitivity analyses were performed to evaluate different scenarios. Results In the intervention group (n = 104) 113 medication changes led to stopping or reducing medication, accounting for averted costs of €22,850. In the control group (n = 112) 39 medication changes led to stopping or reducing medication, accounting for averted costs of €299. The mean labour costs of the intervention were €138 per patient, resulting in saved costs of €61 per patient per six months. Sensitivity analyses showed that if the intervention would be performed by a senior clinical pharmacist, there are no cost savings (€-21), if parts of the intervention would be executed by pharmacy technicians (e.g. administrative tasks), cost savings would be augmented to €87, if outliers in costs associated with medication reduction would be excluded, there are no cost savings (€-35) and if the costs of reduced medication were extrapolated to one year, cost savings would be €260. Conclusion In this study, medication reviews by junior emergency department pharmacists in patients hospitalized after an emergency department visit for an ADE lead to a cost reduction over a six month period. Trial registration The main study is registered on the ISRCTN registry with trial ID ISRCTN12506329 on 06-03-2022.
- Published
- 2024
- Full Text
- View/download PDF
22. Potential healthcare resource use and associated costs of every 2 month injectable cabotegravir plus rilpivirine long-acting regimen implementation in the Spanish National Healthcare System compared to daily oral HIV treatments
- Author
-
Laura-Amanda Vallejo Aparicio, Victoria Neches García, Beatriz Hernández-Novoa, Gregorio Casado, Ferrán Jodar, Marco Pinel, and Daniel Callejo Velasco
- Subjects
Antiretroviral agents ,Cabotegravir ,Costs and cost analysis ,Healthcare resource use ,HIV ,Long-acting injectable ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Introduction HIV treatment currently consists of daily oral antiretroviral therapy (ART). Cabotegravir + rilpivirine long-acting (CAB + RPV LA) is the first ART available in Spain administered every 2 months through intramuscular injection by a healthcare professional (HCP). The objective of this analysis was to assess potential healthcare resource use (HRU) and cost impact of implementing CAB + RPV LA vs. daily oral ART at National Health System (NHS) hospitals. Methods Online quantitative interviews and cost analysis were performed. Infectious disease specialists (IDS), hospital pharmacists (HP) and nurses were asked about their perception of potential differences in HRU between CAB + RPV LA vs. daily oral ART, among other concepts of interest. Spanish official tariffs were applied as unit costs to the HRU estimates (€2022). Results 120 responders (n = 40 IDS, n = 40 HP, n = 40 nurses) estimated an average number of annual visits per patient by speciality (IDS, HP, and nurse, respectively) of 3.3 vs. 3.7; 4.4 vs. 6.2; 6.1 vs. 3.9, for CAB + RPV LA vs. daily oral ART, and 3.0 vs. 3.2; 4.8 vs. 5.8; 6.9 vs. 4.9, respectively when adjusting by corresponding specialist responses. Estimation by the total sample led to an annual total cost per patient of €2,076 vs. €2,473, being €2,032 vs. €2,237 after adjusting by corresponding HCP, for CAB + RPV LA vs. daily oral ART. Conclusions These results suggest that the implementation of CAB + RPV LA in NHS hospitals would not incur in increased HRU-related costs compared to current daily oral ARTs, being potentially neutral or even cost-saving.
- Published
- 2024
- Full Text
- View/download PDF
23. Trends in Medicare claims and costs for field therapies by dermatologists
- Author
-
Kincaid, Colin M, Horton, Luke, Mesinkovska, Natasha A, and Lee, Patrick
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Aged ,United States ,Humans ,Dermatologists ,Medicare ,Keratosis ,Actinic ,Treatment Outcome ,Costs and Cost Analysis ,Diterpenes ,actinic keratoses ,actinic keratosis ,field therapy ,fluorouracil ,imiquimod ,ingenol mebutate ,photodynamic therapy ,Dermatology & Venereal Diseases ,Clinical sciences - Published
- 2023
24. An umbrella review of the acceptability of fiscal and pricing policies to reduce diet-related noncommunicable disease.
- Author
-
Barry, Luke, Kee, Frank, Woodside, Jayne, Cawley, John, Doherty, Edel, Clarke, Mike, Crealey, Grainne, Duggan, Jim, and ONeill, Ciaran
- Subjects
acceptability ,barrier ,diet ,facilitator ,fiscal ,umbrella ,Humans ,Beverages ,Costs and Cost Analysis ,Diet ,Food ,Noncommunicable Diseases ,Systematic Reviews as Topic - Abstract
CONTEXT: Poor diet has been implicated in a range of noncommunicable diseases. Fiscal and pricing policies (FPs) may offer a means by which consumption of food and non-alcoholic beverages with links to such diseases can be influenced to improve public health. OBJECTIVE: To examine the acceptability of FPs to reduce diet-related noncommunicable disease, based on systematic review evidence. DATA SOURCES: MEDLINE, EMBASE, PsychInfo, SCI, SSCI, Web of Science, Scopus, EconLit, the Cochrane Library, Epistemonikos, and the Campbell Collaboration Library were searched for relevant studies published between January 1, 1990 and June 2021. DATA EXTRACTION: The studies included systematic reviews of diet-related FPs and: used real-world evidence; examined real or perceived barriers/facilitators; targeted the price of food or non-alcoholic beverages; and applied to entire populations within a jurisdiction. A total of 9996 unique relevant records were identified, which were augmented by a search of bibliographies and recommendations from an external expert advisory panel. Following screening, 4 systematic reviews remained. DATA ANALYSIS: Quality appraisal was conducted using the AMSTAR 2 tool. A narrative synthesis was undertaken, with outcomes grouped according to the WHO-INTEGRATE criteria. The findings indicated a paucity of high-quality systematic review evidence and limited public support for the use of FPs to change dietary habits. This lack of support was related to a number of factors that included: their perceived potential to be regressive; a lack of transparency, ie, there was mistrust around the use of revenues raised; a paucity of evidence around health benefits; the deliberate choice of rates that were lower than those considered necessary to affect diet; and concerns about the potential of such FPs to harm economic outcomes such as employment. CONCLUSION: The findings underscore the need for high-quality systematic review evidence on this topic, and the importance of responding to public concerns and putting in place mechanisms to address these when implementing FPs. This study was funded by Safefood [02A-2020]. SYSTEMATIC REVIEW REGISTRATION: PROSPERO registration no. CRD42021274454.
- Published
- 2023
25. Up-Front Endoscopy Maximizes Cost-Effectiveness and Cost-Satisfaction in Uninvestigated Dyspepsia.
- Author
-
Wechsler, Emily, Ahuja, Nitin, Brenner, Darren, Chan, Walter, Chang, Lin, Chey, William, Lembo, Anthony, Moshiree, Baha, Nee, Judy, Shah, Shailja, Staller, Kyle, and Shah, Eric
- Subjects
Comparative Effectiveness Research ,Costs and Cost Analysis ,Endoscopy ,Insurance ,Humans ,Dyspepsia ,Cost-Benefit Analysis ,Helicobacter Infections ,Endoscopy ,Gastrointestinal ,Patient Satisfaction ,Helicobacter pylori - Abstract
BACKGROUND & AIMS: Practice guidelines promote a routine noninvasive, non-endoscopic initial approach to investigating dyspepsia without alarm features in young patients, yet many patients undergo prompt upper endoscopy. We aimed to assess tradeoffs among costs, patient satisfaction, and clinical outcomes to inform discrepancy between guidelines and practice. METHODS: We constructed a decision-analytic model and performed cost-effectiveness/cost-satisfaction analysis over a 1-year time horizon on patients with uninvestigated dyspepsia without alarm features referred to gastroenterology. A RAND/UCLA expert panel informed model design. Four competing diagnostic/management strategies were evaluated: prompt endoscopy, testing for Helicobacter pylori and eradicating if present (test-and-treat), testing for H pylori and performing endoscopy if present (test-and-scope), and empiric acid suppression. Outcomes were derived from systematic reviews of clinical trials. Costs were informed by prospective observational cohort studies and national commercial/federal cost databases. Health gains were represented using quality-adjusted life years. RESULTS: From the patient perspective, costs and outcomes were similar for all strategies (maximum out-of-pocket difference of $30 and
- Published
- 2023
26. The Growing Role of Technology in the Care of Older Adults With Diabetes.
- Author
-
Huang, Elbert, Sinclair, Alan, Conlin, Paul, Cukierman-Yaffe, Tali, Hirsch, Irl, Huisingh-Scheetz, Megan, Kahkoska, Anna, Laffel, Lori, Lee, Alexandra, Lee, Sei, Lipska, Kasia, Meneilly, Graydon, Pandya, Naushira, Peek, Monica, Peters, Anne, Pratley, Richard, Sherifali, Diana, Toschi, Elena, Umpierrez, Guillermo, Weinstock, Ruth, and Munshi, Medha
- Subjects
Humans ,Aged ,Diabetes Mellitus ,Blood Glucose ,Caregivers ,Insulin Infusion Systems ,Costs and Cost Analysis - Abstract
The integration of technologies such as continuous glucose monitors, insulin pumps, and smart pens into diabetes management has the potential to support the transformation of health care services that provide a higher quality of diabetes care, lower costs and administrative burdens, and greater empowerment for people with diabetes and their caregivers. Among people with diabetes, older adults are a distinct subpopulation in terms of their clinical heterogeneity, care priorities, and technology integration. The scientific evidence and clinical experience with these technologies among older adults are growing but are still modest. In this review, we describe the current knowledge regarding the impact of technology in older adults with diabetes, identify major barriers to the use of existing and emerging technologies, describe areas of care that could be optimized by technology, and identify areas for future research to fulfill the potential promise of evidence-based technology integrated into care for this important population.
- Published
- 2023
27. Medical costs of Swedish nursing home residents at the end of life: a retrospective observational registry study
- Author
-
Dag Salaj, Torbjörn Schultz, and Peter Strang
- Subjects
Nursing homes ,End-of-life ,Palliative care ,Health care costs ,Costs and cost analysis ,Frailty ,Geriatrics ,RC952-954.6 - Abstract
Abstract Background There are many studies of medical costs in late life in general, but nursing home residents’ needs and the costs of external medical services and interventions outside of nursing home services are less well described. Methods We examined the direct medical costs of nursing home residents in their last year of life, as well as limited to the period of stay in the nursing home, adjusted for age, sex, Hospital Frailty Risk Score (HFRS), and diagnosis of dementia or advanced cancer. This was an observational retrospective study of registry data from all diseased nursing home residents during the years 2015–2021 using healthcare consumption data from the Stockholm Regional Council, Sweden. T tests, Wilcoxon rank sum tests and chi-square tests were used for comparisons of groups, and generalized linear models (GLMs) were constructed for univariable and multivariable linear regressions of health cost expenditures to calculate risk ratios (RRs) with 95% confidence intervals (95% CIs). Results According to the adjusted (multivariable) models for the 38,805 studied nursing home decedents, when studying the actual period of stay in nursing homes, we found significantly greater medical costs associated with male sex (RR 1.29 (1.25–1.33), p
- Published
- 2024
- Full Text
- View/download PDF
28. Forecasting the Economic Burden of Cardiovascular Disease and Stroke in the United States Through 2050: A Presidential Advisory From the American Heart Association.
- Author
-
Kazi, Dhruv S., Elkind, Mitchell S. V., Deutsch, Anne, Dowd, William N., Heidenreich, Paul, Khavjou, Olga, Mark, Daniel, Mussolino, Michael E., Ovbiagele, Bruce, Patel, Sonali S., Poudel, Remy, Weittenhiller, Ben, Powell-Wiley, Tiffany M., and Maddox, Karen E. Joynt
- Subjects
- *
ECONOMIC forecasting , *STROKE , *CARDIOVASCULAR diseases , *STROKE units , *HEART failure , *CARDIOVASCULAR diseases risk factors , *MEDICAL care costs , *CORONARY disease - Abstract
BACKGROUND: Quantifying the economic burden of cardiovascular disease and stroke over the coming decades may inform policy, health system, and community-level interventions for prevention and treatment. METHODS: We used nationally representative health, economic, and demographic data to project health care costs attributable to key cardiovascular risk factors (hypertension, diabetes, hypercholesterolemia) and conditions (coronary heart disease, stroke, heart failure, atrial fibrillation) through 2050. The human capital approach was used to estimate productivity losses from morbidity and premature mortality due to cardiovascular conditions. RESULTS: One in 3 US adults received care for a cardiovascular risk factor or condition in 2020. Annual inflation-adjusted (2022 US dollars) health care costs of cardiovascular risk factors are projected to triple between 2020 and 2050, from $400 billion to $1344 billion. For cardiovascular conditions, annual health care costs are projected to almost quadruple, from $393 billion to $1490 billion, and productivity losses are projected to increase by 54%, from $234 billion to $361 billion. Stroke is projected to account for the largest absolute increase in costs. Large relative increases among the Asian American population (497%) and Hispanic American population (489%) reflect the projected increases in the size of these populations. CONCLUSIONS: The economic burden of cardiovascular risk factors and overt cardiovascular disease in the United States is projected to increase substantially in the coming decades. Development and deployment of cost-effective programs and policies to promote cardiovascular health are urgently needed to rein in costs and to equitably enhance population health. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
29. Implementation, intervention, and downstream costs for implementation of a multidisciplinary complex pain clinic in the Veterans Health Administration.
- Author
-
Daniels, Sarah I., Cave, Shayna, Wagner, Todd H., Perez, Taryn A., Edmond, Sara N., Becker, William C., and Midboe, Amanda M.
- Subjects
- *
VETERANS' health , *HOSPICE patients , *COST accounting , *COST , *BUDGET , *PAIN clinics , *CANCER pain - Abstract
Objective Data Sources and Study Setting Study Design Data Collection/Extraction Methods Principal Findings Conclusions To determine the budget impact of implementing multidisciplinary complex pain clinics (MCPCs) for Veterans Health Administration (VA) patients living with complex chronic pain and substance use disorder comorbidities who are on risky opioid regimens.We measured implementation costs for three MCPCs over 2 years using micro‐costing methods. Intervention and downstream costs were obtained from the VA Managerial Cost Accounting System from 2 years prior to 2 years after opening of MCPCs.Staff at the three VA sites implementing MCPCs were supported by Implementation Facilitation. The intervention cohort was patients at MCPC sites who received treatment based on their history of chronic pain and risky opioid use. Intervention costs and downstream costs were estimated with a quasi‐experimental study design using a propensity score‐weighted difference‐in‐difference approach. The healthcare utilization costs of treated patients were compared with a control group having clinically similar characteristics and undergoing the standard route of care at neighboring VA medical centers. Cancer and hospice patients were excluded.Activity‐based costing data acquired from MCPC sites were used to estimate implementation costs. Intervention and downstream costs were extracted from VA administrative data.Average Implementation Facilitation costs ranged from $380 to $640 per month for each site. Upon opening of three MCPCs, average intervention costs per patient were significantly higher than the control group at two intervention sites. Downstream costs were significantly higher at only one of three intervention sites. Site‐level differences were due to variation in inpatient costs, with some confounding likely due to the COVID‐19 pandemic. This evidence suggests that necessary start‐up investments are required to initiate MCPCs, with allocations of funds needed for implementation, intervention, and downstream costs.Incorporating implementation, intervention, and downstream costs in this evaluation provides a thorough budget impact analysis, which decision‐makers may use when considering whether to expand effective programming. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
30. Análisis de minimización de costos del abastecimiento de dispositivos de presión aérea positiva para el tratamiento de la apnea del sueño.
- Author
-
Serrano Salinas, Laura, Mancilla Mejía, Francisco Javier, Méndez Saucedo, Luis Miguel, Martínez Navez, Jesús Salatiel, Sansores Martínez, Diana Nicte-Ha, Orbelin Mérida, Yuren, and Pérez Garmendia, Roxana
- Abstract
OBJECTIVE: To compare costs of positive air pressure device supply modalities (leasing vs purchase) to determine which implies a minimization of expense. MATERIALS AND METHODS: Operational, quantitative, descriptive, observational and prospective study. All eligible patients over 18 years of age were included, obtained from the database of a sleep clinic at a tertiary care hospital in Mexico City, with a diagnosis of obstructive sleep apnea-hypopnea syndrome in its different degrees of severity and under treatment with positive air pressure devices, from March 1st to June 30, 2022. Direct and indirect costs were considered using the micro-cost method, contemplating all the components of resource use, uncertainty, assumptions with long-term projection, including adjustment and incremental analysis according to the temporal differential, scenarios and assumptions for each modality. RESULTS: Two hundred seventy-nine patients were included. The estimate of care costs under the leasing scheme was 5.35 times higher compared to the 10-year purchase modality. CONCLUSIONS: The results reinforce the position that the purchase alternative minimizes costs, and should be considered the most convenient choice in the hospital center where it was developed. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Physician and informal care use explained by the Pediatric Quality of Life Inventory (PedsQL) in children with suspected genetic disorders.
- Author
-
Berkalieva, Asem, Kelly, Nicole R., Fisher, Ashley, Hohmann, Samuel F., Abul-Husn, Noura S., Greally, John M., Horowitz, Carol R., Wasserstein, Melissa P., Kenny, Eimear E., Gelb, Bruce D., and Ferket, Bart S.
- Subjects
- *
PHYSICIAN services utilization , *QUALITY of life , *GENETIC disorders , *PHYSICIANS , *MEDICAL needs assessment , *ELDER care - Abstract
Purpose: To examine associations between Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales and PedsQL Infant Scales with formal health care resource utilization (HCRU) and informal caregiver burden. Methods: We studied a pediatric cohort of 837 patients (median age: 8.4 years) with suspected genetic disorders enrolled January 2019 through July 2021 in the NYCKidSeq program for diagnostic sequencing. Using linked ~ nine-month longitudinal survey and physician claims data collected through May 2022, we modeled the association between baseline PedsQL scores and post-baseline HCRU (median follow-up: 21.1 months) and informal care. We also assessed the longitudinal change in PedsQL scores with physician services using linear mixed-effects models. Results: Lower PedsQL total and physical health scores were independently associated with increases in 18-month physician services, encounters, and weekly informal care. Comparing low vs. median total scores, increases were 10.6 services (95% CI: 1.0-24.6), 3.3 encounters (95% CI: 0.5–6.8), and $668 (95% CI: $350–965), respectively. For the psychosocial domain, higher scores were associated with decreased informal care. Based on adjusted linear mixed-effects modeling, every additional ten physician services was associated with diminished improvement in longitudinal PedsQL total score trajectories by 1.1 point (95% confidence interval: 0.6–1.6) on average. Similar trends were observed in the physical and psychosocial domains. Conclusion: PedsQL scores were independently associated with higher utilization of physician services and informal care. Moreover, longitudinal trajectories of PedsQL scores became less favorable with increased physician services. Adding PedsQL survey instruments to conventional measures for improved risk stratification should be evaluated in further research. Plain English summary: The Pediatric Quality of Life Inventory (PedsQL) is widely used to measure health-related quality of life in pediatric patients; however, few studies have examined whether the PedsQL is indicative of longitudinal outcomes of morbidity and health care needs. This study captures associations between PedsQL scores with utilization of physician and informal care in children with suspected genetic disorders. We demonstrate that lower PedsQL total and physical health scores are independently associated with greater utilization of physician services and informal care. Moreover, longitudinal trajectories of PedsQL scores become less favorable with increased physician services. Results can inform future applications of PedsQL instruments. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
32. The cost of providing care by family and friends (informal care) in the last year of life: A population observational study.
- Author
-
Johnson, Miriam J, Currow, David C, Chynoweth, Jade, Weatherly, Helen, Keser, Gamze, Hutchinson, Ann, Jones, Annie, Dunn, Laurie, and Allgar, Victoria
- Subjects
- *
HEALTH services accessibility , *DATA analysis , *PLACE of death , *RESEARCH funding , *HUMANITY , *COST analysis , *SCIENTIFIC observation , *MEDICAL care , *INTERVIEWING , *SEX distribution , *QUESTIONNAIRES , *FAMILY relations , *MULTIVARIATE analysis , *FAMILIES , *AGE distribution , *CAUSES of death , *HELP-seeking behavior , *BEREAVEMENT , *MEMORY , *STATISTICS , *TERMINAL care , *FRIENDSHIP , *REGRESSION analysis , *PERSONAL grooming , *EVALUATION - Abstract
Introduction: Little is known about replacement costs of care provided by informal carers during the last year of life for people dying of cancer and non-cancer diseases. Aim: To estimate informal caregiving costs and explore the relationship with carer and decedent characteristics. Design: National observational study of bereaved carers. Questions included informal end-of-life caregiving into the 2017 Health Survey for England including estimated recalled frequency, duration and intensity of care provision. We estimated replacement costs for a decedent's last year of life valuing time at the price of a substitutable activity. Spearman rank correlations and multivariable linear regression were used to explore relationships with last year of life costs. Setting/participants: Adult national survey respondents – England. Results: A total of 7997 adults were interviewed from 5767/9612 (60%) of invited households. Estimated replacement costs of personal care and other help were £27,072 and £13,697 per carer and a national cost of £13.2 billion and £15.5 billion respectively. Longer care duration and intensity, older age, death at home (lived together), non-cancer cause of death and greater deprivation were associated with increased costs. Female sex, and not accessing 'other care services' were related to higher costs for other help only. Conclusion: We provide a first adult general population estimate for replacement informal care costs in the last year of life of £41,000 per carer per decedent and highlight characteristics associated with greater costs. This presents a major challenge for future universal care coverage as the pool of people providing informal care diminish with an ageing population. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Medical costs of Swedish nursing home residents at the end of life: a retrospective observational registry study.
- Author
-
Salaj, Dag, Schultz, Torbjörn, and Strang, Peter
- Subjects
NURSING home residents ,MEDICAL care costs ,DISEASE risk factors ,NURSING home care ,NURSING care facilities ,NURSING services - Abstract
Background: There are many studies of medical costs in late life in general, but nursing home residents' needs and the costs of external medical services and interventions outside of nursing home services are less well described. Methods: We examined the direct medical costs of nursing home residents in their last year of life, as well as limited to the period of stay in the nursing home, adjusted for age, sex, Hospital Frailty Risk Score (HFRS), and diagnosis of dementia or advanced cancer. This was an observational retrospective study of registry data from all diseased nursing home residents during the years 2015–2021 using healthcare consumption data from the Stockholm Regional Council, Sweden. T tests, Wilcoxon rank sum tests and chi-square tests were used for comparisons of groups, and generalized linear models (GLMs) were constructed for univariable and multivariable linear regressions of health cost expenditures to calculate risk ratios (RRs) with 95% confidence intervals (95% CIs). Results: According to the adjusted (multivariable) models for the 38,805 studied nursing home decedents, when studying the actual period of stay in nursing homes, we found significantly greater medical costs associated with male sex (RR 1.29 (1.25–1.33), p < 0.0001) and younger age (65–79 years vs. ≥90 years: RR 1.92 (1.85–2.01), p < 0.0001). Costs were also greater for those at risk of frailty according to the Hospital Frailty Risk Score (HFRS) (intermediate risk: RR 3.63 (3.52–3.75), p < 0.0001; high risk: RR 7.84 (7.53–8.16), p < 0.0001); or with advanced cancer (RR 2.41 (2.26–2.57), p < 0.0001), while dementia was associated with lower medical costs (RR 0.54 (0.52–0.55), p < 0.0001). The figures were similar when calculating the costs for the entire last year of life (regardless of whether they were nursing home residents throughout the year). Conclusions: Despite any obvious explanatory factors, male and younger residents had higher medical costs at the end of life than women. Having a risk of frailty or a diagnosis of advanced cancer was strongly associated with higher costs, whereas a dementia diagnosis was associated with lower external, medical costs. These findings could lead us to consider reimbursement models that could be differentiated based on the observed differences. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. An exploratory analysis of the cost‐effectiveness of insulin glargine 300 units/mL versus insulin glargine 100 units/mL over a lifetime horizon using the BRAVO diabetes model.
- Author
-
Shao, Hui, Shi, Lizheng, Fonseca, Vivian, Alsaleh, Abdul Jabbar Omar, Gill, Jasvinder, and Nicholls, Charlie
- Subjects
- *
QUALITY-adjusted life years , *COST effectiveness , *SECONDARY analysis , *INSURANCE , *RESEARCH funding , *INSULIN derivatives , *COST analysis , *TREATMENT effectiveness , *TYPE 2 diabetes , *RESEARCH , *MEDICAL care costs , *EVALUATION , *DISEASE complications - Abstract
Background: This analysis assessed the cost‐effectiveness of insulin glargine 300 units/mL (Gla‐300) versus insulin glargine 100 units/mL (Gla‐100) in insulin‐naïve adults with type 2 diabetes (T2D) inadequately controlled with oral antidiabetic drugs (OADs). Methods: Costs and outcomes for Gla‐300 versus Gla‐100 from a US healthcare payer perspective were assessed using the BRAVO diabetes model. Baseline clinical data were derived from EDITION‐3, a 12‐month randomized controlled trial comparing Gla‐300 with Gla‐100 in insulin‐naïve adults with inadequately controlled T2D on OADs. Treatment costs were calculated based on doses observed in EDITION‐3 and 2020 US net prices, while costs for complications were based on published literature. Lifetime costs ($US) and quality‐adjusted life‐years (QALYs) were predicted and used to calculate incremental cost‐effectiveness ratio (ICER) estimates; extensive scenario and sensitivity analyses were conducted. Results: Lifetime medical costs were estimated to be $353,441 and $352,858 for individuals receiving Gla‐300 and Gla‐100 respectively; insulin costs were $52,613 and $50,818. Gla‐300 was associated with a gain of 8.97 QALYs and 21.12 life‐years, while Gla‐100 was associated with a gain of 8.89 QALYs and 21.07 life‐years. This resulted in an ICER of $7522/QALY gained for Gla‐300 versus Gla‐100. Thus, Gla‐300 was cost‐effective versus Gla‐100 based on a willingness‐to‐pay threshold of $50,000/QALY. Compared with Gla‐100, Gla‐300 provided a net monetary benefit of $3290. Scenario and sensitivity analyses confirmed the robustness of the base case. Conclusion: Gla‐300 may be a cost‐effective treatment option versus Gla‐100 over a lifetime horizon for insulin‐naïve people in the United States with T2D inadequately controlled on OADs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Estimating the Costs of End-of-Life Care in Patients With Advanced Cancer From the Perspective of an Insurance Organization: A Cross-Sectional Study in Iran.
- Author
-
Zafari, Ali, Mehdizadeh, Parisa, Bahadori, Mohammadkarim, Dopeykar, Nooredin, Teymourzadeh, Ehsan, and Ravangard, Ramin
- Abstract
Cancers are significant medical conditions that contribute to the rising costs of healthcare systems and chronic diseases. This study aimed to estimate the average costs of medical services provided to patients with advanced cancers at the end of life (EOL). We analyzed data from the Sata insurance claim database and the Health Information System of Baqiyatallah hospital in Iran. The study included all adult decedents who had advanced cancer without comorbidities, died between March 2020 and September 2020, and had a history of hospitalization in the hospital. We calculated the average total cost of healthcare services per patient during the EOL period, including both cancer-related and noncancer-related costs. A total of 220 patients met the inclusion criteria. The average duration of the EOL period for these patients was 178 days, with an average total cost of $8278 (SD $5698) for men and $9396 (SD $6593) for women. Cancer-related costs accounted for 64.42% of the total costs, including inpatient and outpatient services. Among these costs, hospitalization was the primary cost driver and had the greatest impact on EOL costs. This observation was supported by the multiple linear regression model, which suggested that hospitalization in the final days of life could potentially drive costs in these patients. Notably, no specialized palliative care was provided to the patients included in this study. The results demonstrate that there is a significant rise in costs of care in patients receiving routine cancer care rather than optimized EOL care. • Patients who die in hospitals incur significantly higher costs than those who die in other settings, such as at home or in a hospice. • This raises questions about the preference for hospital care during this period, given that many patients may prefer to die in a more comfortable and familiar setting. • The study highlights the need for effective cost-management strategies to reduce the financial burden of end-of-life cancer care. • The authors urge decision-makers, especially in less-developed or developing countries, to explore home-based and palliative care options, given that these can improve the quality of care while reducing costs. • The study also underscores the need for informed decision-making regarding resource allocation. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Clinical outcomes and direct cost analysis of rotator cuff repair surgery
- Author
-
Rafael Pierami, Eliane Antonioli, Isabela Queiros Castro, Paula Fairbanks, Felipe Giorgi Manente, and Mario Lenza
- Subjects
Rotator cuff ,Shoulder pain ,Cost-effectiveness analysis ,Costs and cost analysis ,Health care costs ,Treatment outcomes ,Arthroscopy ,Orthopedic procedures ,Medicine - Abstract
ABSTRACT Objective The purpose of this study was to evaluate the clinical and functional outcomes in patients who underwent surgical treatment for rotator cuff tears using open and arthroscopic techniques, and to evaluate the direct costs involved. Methods Retrospective cohort study with analysis of the data of patients who were referred to two private hospitals in Sao Paulo, Brazil for surgical repair of the rotator cuff from January 2018 to September 2019. Clinical outcomes were assessed using functional scores (SPADI and QuickDASH) and a quality of life questionnaire (EuroQoL). Procedure costs were calculated relative to each hospital’s costliest procedure. Results Data from 362 patients were analyzed. The mean patient age was 57 years (SD= 10.46), with a slight male predominance (53.9%). Arthroscopic procedures were more common than open procedures (95.6% versus 4.4%). Significant clinical improvement was reported in 84.8% of the patients. The factors associated with increased surgery costs were arthroscopic technique (increase of 29.2%), age (increase of 0.6% per year), and length of stay (increase of 18.9% per day of hospitalization). Conclusion Rotator cuff repair surgery is a highly effective procedure, associated with favorable clinical outcomes and improvement in life quality, and low rates of complications. Arthroscopic surgery tends to be costlier than open surgery.
- Published
- 2024
- Full Text
- View/download PDF
37. Should case management be considered a component of obstetrical interventions for pregnancies at risk of preterm birth?
- Author
-
Garite, Thomas J and Manuck, Tracy A
- Subjects
Paediatrics ,Reproductive Medicine ,Biomedical and Clinical Sciences ,Health Services ,Perinatal Period - Conditions Originating in Perinatal Period ,Prevention ,Clinical Research ,Pediatric ,Infant Mortality ,Mind and Body ,Preterm ,Low Birth Weight and Health of the Newborn ,Reproductive health and childbirth ,Good Health and Well Being ,Pregnancy ,Female ,Infant ,Newborn ,Humans ,Premature Birth ,Case Management ,Infant ,Premature ,Progestins ,Costs and Cost Analysis ,case management ,case managers ,nutrition counseling ,prematurity ed ,ucation ,preterm birth ,psychosocial support ,smoking cessation ,substance abuse ,counseling ,prematurity education ,substance abuse counseling ,Paediatrics and Reproductive Medicine ,Obstetrics & Reproductive Medicine ,Reproductive medicine - Abstract
Preterm birth remains the leading cause of morbidity and mortality among nonanomalous neonates in the United States. Unfortunately, preterm birth rates remain high despite current medical interventions such as progestogen supplementation and cerclage placement. Case management, which encompasses coordinated care aimed at providing a more comprehensive and supportive environment, is a key component in improving health and reducing costs in other areas of medicine. However, it has not made its way into the general lexicon and practice of obstetrical care. Case management intended for decreasing prematurity or ameliorating its consequences may include specialty clinics, social services, coordination of specialty services such as nutrition counseling, home visits or frequent phone calls by specially trained personnel, and other elements described herein. It is not currently included in nor is it advocated for as a recommended prematurity prevention approach in the American College of Obstetricians and Gynecologists or Society for Maternal-Fetal Medicine guidelines for medically indicated or spontaneous preterm birth prevention. Our review of existing evidence finds consistent reductions or trends toward reductions in preterm birth with case management, particularly among individuals with high a priori risk of preterm birth across systematic reviews, metaanalyses, and randomized controlled studies. These findings suggest that case management has substantial potential to improve the environmental, behavioral, social, and psychological factors with patients at risk of preterm birth.
- Published
- 2023
38. Health economics and financing.
- Author
-
Getzen, Thomas E. and Kobernick, Michael S.
- Subjects
Economics, Medical ,Costs and Cost Analysis ,Delivery of Health Care -- economics ,Health Care Reform -- economics - Abstract
Summary: "Health Economics and Financing is a primer for the economic analysis of medical markets. Its intended audiences are students of medicine, public health, policy, and administration who wish to engage the central economic issues of their field without prolonged preparatory work; beginning students in economics who wish to study an applied area in detail without recourse to extensive mathematical manipulation; and more advanced students in economics who may be familiar with analytical techniques but lack knowledge of the many institutional features that make the study of health and health care so unique and rewarding. This book draws upon the work of many scholars, but in keeping with its design as a primer for introducing students to the principles and concepts of health economics rather than its literature and research methods, the use of attribution, footnotes, and references is purposely limited. Suggestions for additional reading and more advanced source materials and databases are listed at the end of each chapter and are available on the instructor's website at www.wiley.com/go/getzen/healtheconomics6e. The first eleven chapters use a flow-of-funds approach to investigate the sources and uses of financing and to explore the incentives and organizational structure of the health care system. Transactions between patients and physicians (and others) are examined to see how profits are made, costs covered, contracts written (or implied), and regulations formed. The long-term consequences of exchanging services for money in a particular way are revealed by exploring the historical development of those distinctive features that characterize the industrial organization of health care: licensure, third-party insurance, nonprofit hospitals, and government regulation. The last five chapters take a wider macroeconomic perspective in order to explore the dynamics of change within the health care system and to explicitly consider determinants of national health spending and the role of governments in public and private health"-- Provided by publisher.
- Published
- 2022
39. 3D printing vs traditional workflow for the fabrication of mandibular implant overdentures: study protocol for a mixed-methods cross-over RCT
- Author
-
Dana Jafarpour, Nesma El-Amier, Jocelyne Feine, Christophe Bedos, Samer Abi-Nader, Shahrokh Esfandiari, Tibor Shuster, Elizabeth Zimmermann, and Raphael de Souza
- Subjects
3D printing ,CAD/CAM ,Mandibular overdenture ,Costs and cost analysis ,Cross-over studies ,Dental care for aged ,Medicine (General) ,R5-920 - Abstract
Abstract Background Complete tooth loss is a significant global oral health issue, particularly impacting older individuals with lower socioeconomic status. Computer-assisted technologies enhance oral healthcare access by the elderly. Despite promising in vitro reports on digital denture materials, evidence from randomized clinical trials (RCTs) is lacking to verify their performance. This cross-over RCT will investigate whether 3D-printed implant-retained mandibular overdentures (IMO) are more satisfactory for edentulous seniors than those made through traditional methods. Methods/design We will recruit 26 completely edentulous participants (any sex/gender) based on the following eligibility criteria: age ≥ 60 years, no tooth extraction in the past 12 months, two implants in the lower jaw, and need for new dentures in both jaws. Each participant will receive two denture pairs, either manufactured by 3D printing or traditionally, to be worn in a random order. A timeline of 3 months with each denture pair will be considered for outcome assessment (total: 6 months). Patient satisfaction with dentures will be measured by the McGill Denture Satisfaction Questionnaire. We will evaluate other patient-reported outcomes (including oral health-related quality of life) as well as clinician-assessed quality and cost. At the end of the trial, participants will choose which denture pair they wish to keep and interviewed about their experiences with the 3D-printed IMO. The quantitative and qualitative data will be incorporated through an explanatory mixed-methods strategy. A final quantitative assessment will happen after 12 months with the preferred IMO to assess the long-term performance and maintenance needs. Discussion This mixed-methods RCT will explore patient experiences with 3D-printed IMOs, aiming to assess the potential for altering clinical practice and dental public health policies. Our results will inform policies by showing whether 3D printing offers comparable outcomes at lower costs, facilitating greater access to oral care for the elderly. Trial registration ClinicalTrials.gov, NCT06155630, Registered on 04 December 2023. https://classic.clinicaltrials.gov/ct2/show/NCT06155630
- Published
- 2024
- Full Text
- View/download PDF
40. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions
- Author
-
Mark H. Rozenbaum, Erica Chilson, Raymond Farkouh, Liping Huang, Alejandro Cane, Adriano Arguedas, Maria J. Tort, Vincenza Snow, Ahuva Averin, Derek Weycker, Dhwani Hariharan, and Mark Atwood
- Subjects
Children ,Costs and cost analysis ,Immunization ,Pneumonia ,Streptococcus pneumoniae ,Vaccination ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Introduction A 20-valent pneumococcal conjugate vaccine (PCV20) was recently recommended for use among US children. We evaluated the cost-effectiveness of PCV20 among children aged 6 years with chronic medical conditions (CMC+) and children aged 6 years with immunocompromising conditions (IC) versus one and two doses of 23-valent pneumococcal polysaccharide vaccine (PPSV23), respectively. Methods A probabilistic model was employed to depict 10-year risk of clinical outcomes and economic costs of pneumococcal disease, reduction in life years from premature death, and expected impact of vaccination among one cohort of children with CMC+ and IC aged 6 years. Vaccine uptake was assumed to be 20% for both PCV20 and PPSV23. Cost per quality-adjusted life year (QALY) gained was evaluated from the US societal and healthcare system perspectives; deterministic and probabilistic sensitivity analyses (DSA/PSA) were also conducted. Results Among the 226,817 children with CMC+ aged 6 years in the US, use of PCV20 (in lieu of PPSV23) was projected to reduce the number cases of pneumococcal disease by 5203 cases, medical costs by US$8.7 million, and nonmedical costs by US$6.2 million. PCV20 was the dominant strategy versus PPSV23 from both the healthcare and societal perspectives. In the PSA, 99.9% of the 1000 simulations yielded a finding of dominance for PCV20. Findings in analyses of children with IC aged 6 years in the USA were comparable (i.e., PCV20 was the dominant vaccination strategy). Scenario analyses showed that increasing PCV20 uptake to 100% could potentially prevent > 22,000 additional cases of pneumococcal disease and further reduce medical and nonmedical costs by US$70.0 million among children with CMC+ and IC. Conclusions Use of PCV20 among young children with CMC+ and IC in the USA would reduce the clinical burden of pneumococcal disease and yield overall cost savings from both the US healthcare system and societal perspectives. Higher PCV20 uptake could further reduce the number of pneumococcal disease cases in this population.
- Published
- 2024
- Full Text
- View/download PDF
41. Costs of distributing HIV self-testing kits in Eswatini through community and workplace models
- Author
-
Kathleen McGee, Marc d’Elbée, Ralitza Dekova, Linda A. Sande, Lenhle Dube, Sanele Masuku, Makhosazana Dlamini, Collin Mangenah, Lawrence Mwenge, Cheryl Johnson, Karin Hatzold, Melissa Neuman, Gesine Meyer-Rath, and Fern Terris-Prestholt
- Subjects
HIV ,HIV self-testing ,Costs and cost analysis ,Community ,Workplace ,Eswatini ,Infectious and parasitic diseases ,RC109-216 - Abstract
Abstract Background This study evaluates the implementation and running costs of an HIV self-testing (HIVST) distribution program in Eswatini. HIVST kits were delivered through community-based and workplace models using primary and secondary distribution. Primary clients could self-test onsite or offsite. This study presents total running economic costs of kit distribution per model between April 2019 and March 2020, and estimates average cost per HIVST kit distributed, per client self-tested, per client self-tested reactive, per client confirmed positive, and per client initiating antiretroviral therapy (ART). Methods Distribution data and follow-up phone interviews were analysed to estimate implementation outcomes. Results were presented for each step of the care cascade using best-case and worst-case scenarios. A top-down incremental cost-analysis was conducted from the provider perspective using project expenditures. Sensitivity and scenario analyses explored effects of economic and epidemiological parameters on average costs. Results Nineteen thousand one hundred fifty-five HIVST kits were distributed to 13,031 individuals over a 12-month period, averaging 1.5 kits per recipient. 83% and 17% of kits were distributed via the community and workplace models, respectively. Clients reached via the workplace model were less likely to opt for onsite testing than clients in the community model (8% vs 29%). 6% of onsite workplace testers tested reactive compared to 2% of onsite community testers. Best-case scenario estimated 17,458 (91%) clients self-tested, 633 (4%) received reactive-test results, 606 (96%) linked to confirmatory testing, and 505 (83%) initiated ART. Personnel and HIVST kits represented 60% and 32% of total costs, respectively. Average costs were: per kit distributed US$17.23, per client tested US$18.91, per client with a reactive test US$521.54, per client confirmed positive US$550.83, and per client initiating ART US$708.60. Lower rates for testing, reactivity, and linkage to care in the worst-case scenario resulted in higher average costs along the treatment cascade. Conclusion This study fills a significant evidence gap regarding costs of HIVST provision along the client care cascade in Eswatini. Workplace and community-based distribution of HIVST accompanied with effective linkage to care strategies can support countries to reach cascade objectives.
- Published
- 2024
- Full Text
- View/download PDF
42. A quality appraisal of economic evaluations of community water fluoridation: A systematic review.
- Author
-
Cronin, Jodi, Moore, Stephen, Harding, Máiréad, Whelton, Helen, and Woods, Noel
- Abstract
Objectives: To critically appraise the methodological conduct and reporting quality of economic evaluations (EE) of community water fluoridation (CWF). Methods: A systematic literature search was conducted in general databases and specialist directories of the economic literature. The Consensus on Health Economic Criteria list (CHEC) appraised the methodological quality while the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) assessed the reporting quality of included studies. Results: A total of 1,138 records were identified, of which 18 met the inclusion criteria. Cost analysis emerged as the most prevalent type of EE, though a growing trend towards conducting full EEs is observed. CHEC revealed the items most frequently unfulfilled were the study design, measurement and valuation of costs and outcomes, while CHEERS also identified reporting deficiencies in these aspects. Furthermore, the review highlights subtleties in methodological aspects that may not be discerned by CHEC, such as the estimation of the impact of fluoridation and the inclusion of treatment savings within cost estimates. Conclusions: While numerous studies were conducted before publication of these assessment instruments, this review reveals that a noteworthy subset of studies exhibited good methodological conduct and reporting quality. There has been a steady improvement in the methodological and reporting quality over time, with recently published EEs largely adhering to best practice guidelines. The evidence presented will assist policymakers in leveraging the available evidence effectively to inform resource allocation decisions. It may also serve as a resource for researchers to enhance the methodological and reporting standards of future EEs of CWF. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Optimal spatial evaluation of a pro rata vaccine distribution rule for COVID-19
- Author
-
Castonguay, François M, Blackwood, Julie C, Howerton, Emily, Shea, Katriona, Sims, Charles, and Sanchirico, James N
- Subjects
Economics ,Applied Economics ,Immunization ,Vaccine Related ,Prevention ,Infectious Diseases ,3.4 Vaccines ,Prevention of disease and conditions ,and promotion of well-being ,Infection ,Good Health and Well Being ,Humans ,COVID-19 Vaccines ,COVID-19 ,Vaccines ,World Health Organization ,Costs and Cost Analysis - Abstract
The COVID-19 Vaccines Global Access (COVAX) is a World Health Organization (WHO) initiative that aims for an equitable access of COVID-19 vaccines. Despite potential heterogeneous infection levels across a country, countries receiving allotments of vaccines may follow WHO's allocation guidelines and distribute vaccines based on a jurisdictions' relative population size. Utilizing economic-epidemiological modeling, we benchmark the performance of this pro rata allocation rule by comparing it to an optimal one that minimizes the economic damages and expenditures over time, including a penalty representing the social costs of deviating from the pro rata strategy. The pro rata rule performs better when the duration of naturally- and vaccine-acquired immunity is short, when there is population mixing, when the supply of vaccine is high, and when there is minimal heterogeneity in demographics. Despite behavioral and epidemiological uncertainty diminishing the performance of the optimal allocation, it generally outperforms the pro rata vaccine distribution rule.
- Published
- 2023
44. Cost and Utility Estimates per Modified Rankin Scale Score up to 2 Years Post Stroke: Data to Inform Economic Evaluations From a Societal Perspective.
- Author
-
Pinckaers, Florentina M.E., Grutters, Janneke P.C., Huijberts, Ilse, Gabrio, Andrea, Boogaarts, Hieronymus D., Postma, Alida A., van Oostenbrugge, Robert J., van Zwam, Wim H., and Evers, Silvia M.A.A.
- Subjects
- *
STROKE , *COST estimates , *ECONOMIC statistics , *ISCHEMIC stroke , *ENDOVASCULAR surgery , *MULTIPLE imputation (Statistics) - Abstract
Model-based health economic evaluations of ischemic stroke are in need of cost- and utility estimates related to relevant outcome measures. This study aims to describe societal cost- and utility estimates per modified Rankin Scale (mRS)-score at different time points within 2 years post stroke. Included patients had a stroke between 3 months and 2.5 years ago. mRS and EQ-5D-5L were scored during a telephone interview. Based on the interview date, records were categorized into a time point: 3 months (3M; 3-6 months), 1 year (Y1; 6-18 months), or 2 years (Y2; 18-30 months). Patients completed a questionnaire on healthcare utilization and productivity losses in the previous 3 months. Initial stroke hospitalization costs were assessed. Mean costs and utilities per mRS and time point were derived with multiple imputation nested in bootstrapping. Cost at 3 months post stroke were estimated separately for endovascular treatment (EVT)-/non-EVT-patients. 1106 patients were included from 18 Dutch centers. At each time point, higher mRS-scores were associated with increasing average costs and decreasing average utility. Mean societal costs at 3M ranged from €11 943 (mRS 1, no EVT) to €55 957 (mRS 5, no EVT). For Y1, mean costs in the previous 3 months ranged from €885 (mRS 0) to €23 215 (mRS 5), and from €1655 (mRS 0) to €22 904 (mRS 5) for Y2. Mean utilities ranged from 0.07 to 0.96, depending on mRS and time point. The mRS-score is a major determinant of costs and utilities at different post-stroke time points. Our estimates may be used to inform future model-based health economic evaluations. • Model-based health economic evaluations of acute ischemic stroke are in need of cost- and utility estimates related to relevant outcome measures, such as the modified Rankin Scale. • Using prospectively collected data, this cross-sectional study provides cost and utility estimates per modified Rankin Scale score at 3 months, 1 year, and 2 years post stroke. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Optimizing theatre utilization for abscess drainage: going beyond priority categories.
- Author
-
Yang, Phillip F., Builth‐Snoad, Lily, Ng, Kheng‐Seong, Gu, Eva, Errington, Belinda, McBride, Kate E., and Lee, Peter J.
- Subjects
- *
ABSCESSES , *LENGTH of stay in hospitals , *SURGICAL emergencies , *HOSPITAL admission & discharge , *HOSPITAL emergency services , *SURGICAL drainage - Abstract
Background: Day‐only emergency surgery for abscess drainage is poorly implemented in Australia. This study assessed the feasibility, outcomes, cost, and impact of an acute day‐only surgery (ADOS) program. Method: A retrospective pre‐post implementation study of patients requiring abscess drainage in theatre was performed. Following implementation of an ADOS program for abscess management, eligible patients were discharged from the emergency department and prioritized first on the following day's emergency list. Outcomes from the first 12 months of the ADOS era were compared with those of the preceding 6 months (pre‐ADOS). Primary outcome was length of hospital stay (LOS). Secondary outcomes included 30‐day complications, admission costs, and impact on overall emergency theatre workflow (measured by emergency appendicectomy metrics). Results: Overall, 266 patients during the ADOS era (including 95 eligible for the ADOS pathway) were compared with 115 patients during the pre‐ADOS era. Baseline characteristics were comparable. Median LOS was shorter during the ADOS era (21.9 h (IQR 11.8–43.3) vs. 30.1 h (IQR 24.7–48.8), P < 0.001). Median LOS was 10.2 h (IQR 8.9–13.1) for patients on the ADOS pathway. There were no significant differences in 30‐day complications (9.3% vs. 9.5%), emergency department re‐presentations (7.4% vs. 5.1%), or abscess recurrence (5.6% vs. 5.7%). Average cost per patient was lower during the ADOS era ($4155 vs. $4916, p = 0.005). ADOS did not appear to materially impact other emergency procedures. Conclusion: ADOS for abscess drainage is feasible, safe, and produces cost savings, while being implemented without significant additional resources. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. COVID-19 and Acute Myocardial Infarction: Exploring Clinical Factors and Treatment Expenditures.
- Author
-
Rajaie, Soheila, Rezapour, Aziz, Tajdini, Masih, Salehbeygi, Shahrzad, and Azari, Samad
- Subjects
- *
MYOCARDIAL infarction treatment , *MYOCARDIAL infarction , *CROSS-sectional method , *MEDICAL care use , *CHEST pain , *SEX distribution , *COST analysis , *HOSPITAL care , *DESCRIPTIVE statistics , *AGE distribution , *HOSPITAL mortality , *HEART failure , *DATA analysis software , *LENGTH of stay in hospitals , *COVID-19 pandemic , *COVID-19 , *MEDICAL care costs , *ECONOMICS - Abstract
Background: The concurrence of acute myocardial infarction (AMI) with COVID-19 can complicate the clinical conditions of patients and affect the patterns of hospital resource utilization. This study aimed to investigate and analyze the direct treatment costs of AMI patients with concurrent COVID-19. Methods: This cross-sectional study collected and analyzed clinical data, including symptoms, readmission, and interventions, and treatment cost data for all patients at Tehran Heart Center using SPSS26 software. The mean medical costs of patients from January through May 2022 were also calculated. Results: The COVID-19 group was composed of 72.9% male and 27.1% female patients, whereas the non-COVID-19 group consisted of 67.3% male and 32.7% female patients. Most of the patients in the COVID-19 group (60%) were in the elderly age group (>65 y). The length of stay was 8.70±5.84 days for the COVID-19 group and 6.31±4.42 days for the non-COVID-19 group. The mortality rate in the COVID-19 group was 24%, higher than the 5% rate in the other group. Additionally, the average total treatment costs were $6384.54±$6760.13 in the COVID-19 group and $6362.49±$4343.07 in the non-COVID-19 group (P>0.78 and P>0.050). Conclusion: The study found that the COVID-19 group had a significantly higher in-hospital mortality rate than the non-COVID-19 group. During the follow-up period, the incidence of complications (chest pain and heart failure) was higher in the non-COVID-19 group. It also showed that longer hospital stays resulted in higher treatment costs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
47. Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions.
- Author
-
Rozenbaum, Mark H., Chilson, Erica, Farkouh, Raymond, Huang, Liping, Cane, Alejandro, Arguedas, Adriano, Tort, Maria J., Snow, Vincenza, Averin, Ahuva, Weycker, Derek, Hariharan, Dhwani, and Atwood, Mark
- Subjects
- *
PNEUMOCOCCAL vaccines , *PNEUMOCOCCAL meningitis , *MEDICAL care costs , *VACCINATION status , *QUALITY-adjusted life years , *COST effectiveness - Abstract
Introduction: A 20-valent pneumococcal conjugate vaccine (PCV20) was recently recommended for use among US children. We evaluated the cost-effectiveness of PCV20 among children aged 6 years with chronic medical conditions (CMC+) and children aged 6 years with immunocompromising conditions (IC) versus one and two doses of 23-valent pneumococcal polysaccharide vaccine (PPSV23), respectively. Methods: A probabilistic model was employed to depict 10-year risk of clinical outcomes and economic costs of pneumococcal disease, reduction in life years from premature death, and expected impact of vaccination among one cohort of children with CMC+ and IC aged 6 years. Vaccine uptake was assumed to be 20% for both PCV20 and PPSV23. Cost per quality-adjusted life year (QALY) gained was evaluated from the US societal and healthcare system perspectives; deterministic and probabilistic sensitivity analyses (DSA/PSA) were also conducted. Results: Among the 226,817 children with CMC+ aged 6 years in the US, use of PCV20 (in lieu of PPSV23) was projected to reduce the number cases of pneumococcal disease by 5203 cases, medical costs by US$8.7 million, and nonmedical costs by US$6.2 million. PCV20 was the dominant strategy versus PPSV23 from both the healthcare and societal perspectives. In the PSA, 99.9% of the 1000 simulations yielded a finding of dominance for PCV20. Findings in analyses of children with IC aged 6 years in the USA were comparable (i.e., PCV20 was the dominant vaccination strategy). Scenario analyses showed that increasing PCV20 uptake to 100% could potentially prevent > 22,000 additional cases of pneumococcal disease and further reduce medical and nonmedical costs by US$70.0 million among children with CMC+ and IC. Conclusions: Use of PCV20 among young children with CMC+ and IC in the USA would reduce the clinical burden of pneumococcal disease and yield overall cost savings from both the US healthcare system and societal perspectives. Higher PCV20 uptake could further reduce the number of pneumococcal disease cases in this population. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Análisis de costos directos entre las terapias de reemplazo renal en un hospital peruano.
- Author
-
Arellan-Bravo, Luis, Benito-Condor, Briam, and Gutiérrez-Aguado, Alfonso
- Subjects
RENAL replacement therapy ,PERITONEAL dialysis ,COST analysis ,CHRONIC kidney failure ,KIDNEY transplantation - Abstract
Copyright of Acta Médica Peruana is the property of Colegio Medico del Peru and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
49. Cost-Effectiveness Analysis of Sintilimab Plus Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer: A Societal Perspective.
- Author
-
Li, Fuming, Chen, Yingyao, Xiao, Dunming, Jiang, Shan, and Yang, Yi
- Abstract
Introduction: The updated ORIENT-11 study demonstrated that sintilimab, when combined with chemotherapy, had promising survival advantage compared to standard chemotherapy alone in the first-line treatment for previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (nsNSCLC). This study aims to evaluate the cost-effectiveness of sintilimab plus chemotherapy for advanced nsNSCLC from a Chinese societal perspective. Methods: A partitioned survival model with a embedded decision tree was developed to assess the economic value of sintilimab plus chemotherapy over a lifetime horizon. Clinical data was captured from the updated ORIENT-11 study, while costs, health productivity losses, and utility values were collected from a nationwide cross-sectional survey in tertiary hospitals across multiple provinces in China. The primary outcomes were measured using the metrics of quality-adjusted life years (QALYs) and incremental cost-effectiveness ratios (ICER). Costs and health outcomes were discounted at an annual rate of 5% per annum. Sensitivity analyses, including one-way and probabilistic sensitivity analyses, subgroup analyses, and scenario analyses, were performed. Results: Compared to standard chemotherapy, treatment with sintilimab plus chemotherapy incurred a mean total cost of $23,979 and gained 0.98 QALYs over the lifetime horizon, resulting in an ICER of $24,568 per QALY gained. The use of sintilimab accumulated direct non-medical costs of $9262 and indirect costs of $6780 over 16 years. Probabilistic sensitivity analyses showed an 84.2% probability of sintilimab plus chemotherapy being cost-effective at a threshold of three times China's per capita gross domestic product in 2022 ($38,201). The model was most sensitive to the discount rate of QALYs and costs, as well as the costs of pemetrexed, sintilimab, and subsequent therapy in progressive disease state. Subgroup analyses indicated favorable incremental net monetary benefits in all subgroups. Conclusion: Sintilimab plus chemotherapy is a cost-effective first-line treatment therapy for advanced nsNSCLC in China when compared to standard chemotherapy. These findings, along with the improved progression-free survival and overall survival (OS) observed in ORIENT-11, support the use of this regimen in eligible candidates for advanced nsNSCLC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Attributable Cost of Adult Respiratory Syncytial Virus Illness Beyond the Acute Phase.
- Author
-
Averin, Ahuva, Atwood, Mark, Sato, Reiko, Yacisin, Kari, Begier, Elizabeth, Shea, Kimberly, Curcio, Daniel, Houde, Linnea, and Weycker, Derek
- Abstract
Background Estimates of the cost of medically attended lower respiratory tract illness (LRTI) due to respiratory syncytial virus (RSV) in adults, especially beyond the acute phase, is limited. This study was undertaken to estimate the attributable costs of RSV-LRTI among US adults during, and up to 1 year after, the acute phase of illness. Methods A retrospective observational matched-cohort design and a US healthcare claims repository (2016–2019) were employed. The study population comprised adults aged ≥18 years with RSV-LRTI requiring hospitalization (RSV-H), an emergency department visit (RSV-ED), or physician office/hospital outpatient visit (RSV-PO/HO), as well as matched comparison patients. All-cause healthcare expenditures were tallied during the acute phase of illness (RSV-H: from admission through 30 days postdischarge; ambulatory RSV: during the episode) and long-term phase (end of acute phase to end of following 1-year period). Results The study population included 4526 matched pairs of RSV-LRTI and comparison patients (RSV-H: n = 970; RSV-ED: n = 590; RSV-PO/HO: n = 2966). Mean acute-phase expenditures were $42 179 for RSV-H (vs $5154 for comparison patients), $4409 for RSV-ED (vs $377), and $922 for RSV-PO/HO (vs $201). By the end of the 1-year follow-up period, mean expenditures—including acute and long-term phases—were $101 532 for RSV-H (vs $36 302), $48 701 for RSV-ED (vs $27 131), and $28 851 for RSV-PO/HO (vs $20 523); overall RSV-LRTI attributable expenditures thus totaled $65 230, $21 570, and $8327, respectively. Conclusions The cost of RSV-LRTI requiring hospitalization or ambulatory care among US adults is substantial, and the economic impact of RSV-LTRI may extend well beyond the acute phase of illness. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.